Pfizer Inc.
Pfizer Announces Multi-Year Cost Reduction Program
Summary
Pfizer Inc. announced a multi-year program to reduce its cost of goods sold, expected to deliver savings of approximately $1.5 billion by the end of 2027. The program will involve operational efficiencies, network structure changes, and product portfolio enhancements, with one-time costs of about $1.7 billion, primarily for severance and implementation costs, to be recorded in 2024.
Profitelligence Alerts
Get alerts for PFE
Be first to know when Pfizer Inc. files with the SEC.
Filing Categories
Advertisement
About Pfizer Inc.
Pfizer Inc. is a multinational pharmaceutical and biotechnology corporation, recognized for its role in the research, development, and manufacturing of healthcare products. Operating in the health sector, Pfizer focuses on creating innovative medicines and vaccines that significantly improve patients' lives. It is renowned for its contributions to pivotal health areas, such as oncology, immunology, cardiovascular health, and rare diseases. Pfizer maintains a robust pipeline of products at various stages of clinical development, enhancing its market position and impact. The company is instrumental in the global pharmaceutical landscape, contributing to public health with breakthroughs like vaccines and therapies that tackle some of the world's most challenging diseases. Headquartered in New York City, Pfizer plays a critical role in addressing urgent medical needs worldwide and is involved in extensive collaborations with scientific communities and healthcare systems. As a key player in the pharmaceutical industry, Pfizer’s developments and strategic initiatives can influence market trends and health policies, underscoring its importance in the global effort to combat health issues.
Official SEC Documents
Advertisement